239 related articles for article (PubMed ID: 34049505)
1. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
Sharma V; Sharma A; Raina V; Dabkara D; Mohanti BK; Shukla NK; Pathy S; Thulkar S; Deo SVS; Kumar S; Sahoo RK
BMC Cancer; 2021 May; 21(1):630. PubMed ID: 34049505
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for brain metastases in patients with metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Høgdall E; Poulsen TS; Pfeiffer P; Jensen BV; Yilmaz MK; Christensen IJ; Nielsen D
Acta Oncol; 2017 May; 56(5):639-645. PubMed ID: 28447565
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
4. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
Thomay AA; Nagorney DM; Cohen SJ; Sigurdson ER; Truty MJ; Burtness B; Hall MJ; Chun YS
J Gastrointest Surg; 2014 Jan; 18(1):69-74. PubMed ID: 24002765
[TBL] [Abstract][Full Text] [Related]
5. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
[TBL] [Abstract][Full Text] [Related]
6. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?
Lau JWL; Chang HSY; Lee KY; Gwee YX; Lee WQ; Chong CS
ANZ J Surg; 2018 Nov; 88(11):E772-E777. PubMed ID: 29938886
[TBL] [Abstract][Full Text] [Related]
7. Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Tsutsumi S; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Asao T; Kuwano H
Hepatogastroenterology; 2014 May; 61(131):633-7. PubMed ID: 26176048
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Uncu D
J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
[TBL] [Abstract][Full Text] [Related]
9. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
10. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Shitara K; Yuki S; Yamazaki K; Naito Y; Fukushima H; Komatsu Y; Yasui H; Takano T; Muro K
J Cancer Res Clin Oncol; 2013 Apr; 139(4):595-603. PubMed ID: 23250506
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival.
Brouwer NPM; van der Kruijssen DEW; Hugen N; de Hingh IHJT; Nagtegaal ID; Verhoeven RHA; Koopman M; de Wilt JHW
Ann Surg Oncol; 2020 May; 27(5):1580-1588. PubMed ID: 31792717
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A
Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485
[TBL] [Abstract][Full Text] [Related]
13. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
[TBL] [Abstract][Full Text] [Related]
14. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Nitzkorski JR; Farma JM; Watson JC; Siripurapu V; Zhu F; Matteotti RS; Sigurdson ER
Ann Surg Oncol; 2012 Feb; 19(2):379-83. PubMed ID: 21861213
[TBL] [Abstract][Full Text] [Related]
15. Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Ishida H; Kumamoto K; Ishibashi K; Hatano S; Matsuzawa T; Okada N; Kumagai Y; Baba H; Haga N
Tech Coloproctol; 2013 Dec; 17(6):647-52. PubMed ID: 23389285
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Klaver YL; Simkens LH; Lemmens VE; Koopman M; Teerenstra S; Bleichrodt RP; de Hingh IH; Punt CJ
Eur J Surg Oncol; 2012 Jul; 38(7):617-23. PubMed ID: 22572106
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
18. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the requirement of surgical or endoscopic interventions during chemotherapy in patients with uncomplicated colorectal cancer and unresectable synchronous metastases.
Yun JA; Park Y; Huh JW; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
J Surg Oncol; 2014 Dec; 110(7):839-44. PubMed ID: 25043872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
